Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
duloxetine + methylphenidate
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
duloxetine + methylphenidate is a combination pharmacotherapy investigated for the treatment of cocaine use disorder. Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) originally developed by Eli Lilly, while methylphenidate is a central nervous system stimulant that acts as a norepinephrine-dopamine reuptake inhibitor (NDRI). This specific combination was studied in early-phase clinical trials led by Craig Rush at the University of Kentucky, with funding from the National Institute on Drug Abuse (NIDA). The research aimed to evaluate whether the maintenance of these two agents could attenuate the reinforcing, subjective, and physiological effects of cocaine, potentially providing a therapeutic strategy for individuals with cocaine dependence by stabilizing monoamine levels and reducing the drug's rewarding properties.
- Brand names
- CymbaltaMetadateRitalin
- Other names
- duloxetine and methylphenidate combination
02
Targets
SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)
Beyond the preview
Go deeper on duloxetine + methylphenidate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on duloxetine + methylphenidate.